Revenue Breakdown
Composition ()
No data
Revenue Streams
Petmed Express Inc (PETS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reorder sales, accounting for 84.3% of total sales, equivalent to $37.41M. Other significant revenue streams include New order sales and Membership fees. Understanding this composition is critical for investors evaluating how PETS navigates market cycles within the Drug Retailers industry.
Profitability & Margins
Evaluating the bottom line, Petmed Express Inc maintains a gross margin of 22.85%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -16.13%, while the net margin is -19.20%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PETS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, PETS competes directly with industry leaders such as KXIN and OTH. With a market capitalization of $68.81M, it holds a significant position in the sector. When comparing efficiency, PETS's gross margin of 22.85% stands against KXIN's 100.00% and OTH's 12.26%. Such benchmarking helps identify whether Petmed Express Inc is trading at a premium or discount relative to its financial performance.
